MIFEPRISTONE TABLETS

(MIFEPRISTONI COMPRESSI)

Draft proposal for inclusion in *The International Pharmacopoeia*

(27 August 2024)

DRAFT FOR COMMENTS

Please submit your comments through the online platform, PleaseReviewTM

(https://who.pleasereview.net/Main/Default.aspx?action=loaddocument&reviewid=282) If not registered or included in our mailing list, kindly submit your request with your full name, email address and organization/affiliation to

For any technical questions, you may contact Dr Herbert Schmidt, Technical Officer, Norms and Standards for Pharmaceuticals, Technical Standards and Specifications (schmidth@who.int), with a copy to Ms Bezawit Kibret (kibretb@who.int)

Comments should be submitted through the online platform by 27 October 2024. Please note that only comments received by this deadline will be considered for the preparation of this document.

Our working documents are sent out electronically and uploaded into PleaseReviewTM. The working documents are also placed on the WHO Medicines website (https://www.who.int/teams/health-product-and-policy-standards/standards-and-policy-standards/standards-and-policy-standards/standards-and-policy-standards/standards-and-policy-standa specifications/pharmaceuticals/working-documents-public-consultation) under "Working documents in public consultation".

If you wish to receive all our draft guidelines during the course of the year, please send your full name, organization/affiliation and email address to jonessi@who.int, nsp@who.int and your name will be added to our electronic mailing list and review platform.

© World Health Organization 2024

All rights reserved.

This is a draft. The content of this document is not final, and the text may be subject to revisions before publication. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization.

Please send any request for permission to: Ms Sinead Jones, Norms and Standards for Pharmaceuticals, Technical Standards and Specifications, Department of Health Products Policy and Standards, World Health Organization, CH-1211 Geneva 27, Switzerland, email: jonessi@who.int, nsp@who.int.

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft.

However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.

1

2

3

4

5

SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/24.959

MIFEPRISTONE TABLETS

(MIFEPRISTONI COMPRESSI)

Drafting of the monograph by the Secretariat based on information received from manufacturers and found in the public domain

Discussion at the Consultation on Quality Control and Pharmacopoeial Specifications of Medicines

Draft monograph sent out for public consultation.

Presentation to the 58th meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations.

Date

Date

Date

Date

Date

Date

41

37

38

39

40

- 42 [Note from the Secretariat. The monograph on Mifepristone tablets is proposed for
- 43 *inclusion in* The International Pharmacopoeia.

Further follow-up action as required.

- 44 Being one of the first public standards, the monographs on Mifepristone and
- 45 Mifepristone tablets are expected to play an important role in ensuring access to safe,
- 46 effective and acceptable abortion care. Manufacturers, regulatory authorities,
- 47 procurement agencies and other stakeholders are therefore invited to provide their
- 48 feedback.
- 49 The draft monograph is based on information received from manufacturers and found
- 50 in the public domain and on laboratory investigations.
- 51 Draft monographs are subject to change.]

MIFEPRISTONE TABLETS (MIFEPRISTONI COMPRESSI)

- 53 **Category.** Uterotonics.
- 54 **Storage.** Mifepristone tablets should be kept in tightly closed containers and protected
- 55 from light.

52

- Additional information. Strength in the current WHO Model List of Essential
- 57 Medicines: 200 mg. Additional strength available: 600 mg.
- 58 Requirements
- **Definition.** Mifepristone tablets contain not less than 90.0% and not more than 110.0%
- of the amount of Mifepristone ($C_{29}H_{35}NO_2$) stated on the label.
- 61 Identity tests
- Either test A, or any two of tests B, C or D, may be applied.
- 63 A. Carry out the test as described under <u>1.14.1 Chromatography</u>, High-
- performance liquid chromatography, using the conditions given under "Assay"
- with the following modifications: As the detector, use a diode array detector to
- record the UV spectrum of the principal peak in each chromatogram in the
- range of 230 nm to 350 nm. The retention time and the UV spectrum of the
- principal peak in the chromatogram obtained with solution (1) correspond to
- the retention time and the UV spectrum of the peak due to mifepristone in the
- 70 chromatogram obtained with solution (2).
- 71 B. Carry out the test as described under 1.14.1 Chromatography, High-
- 72 performance liquid chromatography, using the conditions given under "Assay".
- The retention time of the principal peak in the chromatogram obtained with
- solution (1) corresponds to the retention time of the peak due to mifepristone in
- 75 the chromatogram obtained with solution (2).

94

95

96

- 76 C. Transfer a quantity of the powdered tablets, nominally containing 10 mg of
 77 Mifepristone, into a 100 mL volumetric flask, add about 60 mL of methanol R,
 78 shake with a mechanical shaker for about 30 minutes, dilute to volume with
 79 methanol R, mix and filter. Dilute 5.0 mL of this solution to 50.0 mL with the
 80 same solvent. The absorption spectrum (1.6) of the resulting solution, when
 81 observed between 230 nm and 350 nm, exhibits two maxima at about 260 nm
 82 and 304 nm.
- Carry out the test as described under 1.14.1 Chromatography, Thin-laver 83 D. chromatography, using silica gel R6 as the coating substance and a mixture of 7 84 volumes of toluene R and 3 volumes of ethyl acetate R as the mobile phase, 85 prepared immediately before use. Apply separately to the plate 5 µL of each of 86 the following two solutions. For solution (A), transfer a quantity of the 87 powdered tablets, nominally containing 10 mg of mifepristone, into a 20 mL 88 volumetric flask, add about 12 mL of methanol R, shake with a mechanical 89 shaker for about 30 minutes, dilute to volume with methanol R, mix and filter. 90 For solution (B), use a solution containing 0.5 mg of mifepristone RS per mL 91 of methanol R. After removing the plate from the chromatographic chamber, 92 allow it to dry in air and examine under ultraviolet light (254 and 360 nm). 93
 - The principal spot in the chromatogram obtained with solution (A) corresponds in position, appearance and intensity with the spot due to mifepristone in the chromatogram obtained with solution (B).
- Dissolution. For 200 mg and 600 mg tablets. Carry out the test described under 5.5

 Dissolution test for oral dosage forms, using as the dissolution medium 900 mL of hydrochloric acid (~0.365 g/L) TS and rotating the paddle at 75 revolutions per minute. At 30 minutes, withdraw a sample of 10 mL of the medium through an in-line filter. Allow the filtered sample to cool to room temperature.

- 102 For 200 mg tablets: dilute 5.0 mL of this solution to 100.0 mL and use it as solution
- 103 (1). For 600 mg tablets: dilute 3.0 mL of this solution to 200.0 mL and use it as
- 104 solution (1).
- For solution (2), transfer 44.0 mg of mifepristone RS into a 200 mL volumetric flask,
- dissolve in dissolution medium, dilute to volume with the same solvent and mix.
- Dilute 5.0 mL of this solution to 100.0 mL with the dissolution medium.
- Measure the absorbance as described under 1.6 Spectrophotometry in the visible and
- ultraviolet regions of solutions (1) and (2) in a cuvette with an optical pathlength of
- 10 mm at about 310 nm, using the dissolution buffer as the blank.
- For each of the tablets tested, calculate the total amount of mifepristone ($C_{29}H_{35}NO_2$)
- in the medium from the results obtained.
- Evaluate the results as described under 5.5 Dissolution test for solid oral dosage
- 114 forms, Acceptance criteria. The amount of mifepristone released is not less than 80%
- (O) of the amount declared on the label.
- 116 [Note from the Secretariat: It is intended to determine the absorptivity value of
- mifepristone during the establishment of mifepristone RS and to use this value for the
- 118 *calculation of the test result.*]
- 119 **Related substances**. Carry out the test as described under 1.14.1 Chromatography,
- High-performance liquid chromatography, using a stainless-steel column (4.6 mm
- 121 x 25 cm) packed with particles of silica gel, the surface of which has been modified
- with chemically bonded octadecylsilyl groups $(5 \mu m)$.¹

¹ A Luna C18(2) column has been found suitable.

- Prepare a phosphate buffer pH 7.0 by dissolving 4.7 g of potassium dihydrogen
- phosphate dihydrate R in 1000 mL of water R and adjusting the pH with at 7.0
- with triethylamine R.
- Use the following conditions for gradient elution:
- mobile phase A: phosphate buffer pH 7.0;
- mobile phase B: acetonitrile R.

Time (minutes)	Mobile phase A (% V/V)	Mobile phase B (% V/V)	Comments
0–26	50	50	Isocratic
26–30	50 to 45	50 to 55	Linear gradient
30–34	45 to 40	55 to 60	Linear gradient
34–40	40 to 35	60 to 65	Linear gradient
40–44	35 to 40	65 to 60	Linear gradient
44–48	40 to 45	60 to 55	Linear gradient
48–52	45 to 50	55 to 50	Return to initial composition
52–60	50	50	Re-equilibration

- Operate with a flow rate of 1.0 mL per minute. Maintain the column temperature
- at 25 °C. Use an ultraviolet spectrophotometer set at a wavelength of 260 nm.
- Prepare the following solutions, using as a diluent a mixture of 45 volumes of
- acetonitrile R and 55 volumes of the phosphate buffer pH 7.0.
- For solution (1), transfer a quantity of the powdered tablets, nominally containing
- 200.0 mg of Mifepristone, into a 200 mL volumetric flask. Add about 150 mL,
- sonicate for 5 minutes and stir magnetically for an additional 30 minutes. Cool to
- room temperature, dilute to volume, mix and filter.
- For solution (2), dilute 1.0 mL of solution (1) to 100.0 mL.

page 7

- For solution (3), dilute 5.0 mL of solution (2) to 50.0 mL.
- For solution (4), dissolve 4 mg of mifepristone impurity B in 10 mL acetonitrile
- 140 R. Dilute 1 mL of this solution to 100 mL with the diluent.
- For solution (5), dilute 1 mL of solution (4) to 10 mL with solution (1).
- Inject 10 μ L each of solutions (1), (2), (3) and (5).
- Use the chromatogram obtained with solution (5) to identify the peaks due to
- mifepristone and impurity B.
- The impurities are eluted, if present, at the following relative retentions with reference
- to mifepristone (retention time about 24 minutes): impurity A about 0.57, impurity B
- about 0.96, and impurity C about x [the value will be determined during the
- verification studies]. The test is not valid unless, in this chromatogram obtained with
- solution (5), the resolution between the peaks due to impurity B and mifepristone is at
- least 1. Also, the test is not valid unless, in the chromatogram obtained with solution
- 151 (3), the peak due to mifepristone is obtained with a signal-to-noise ratio of at least 10.
- In the chromatogram obtained with solution (1):
- the area of any peak corresponding to impurity A, when multiplied by a
- 154 correction factor of 1.53, is not greater than the area of the peak due to
- mifepristone in the chromatogram obtained with solution (2) (1.0 %);
- the area of any other impurity peak is not greater than 0.2 times the area of
- the peak due to mifepristone in the chromatogram obtained with solution
- 158 (2)(0.2%).
- The sum of the areas of all impurity peaks, excluding the area of any peak
- corresponding to impurity A, is not greater than the area of the peak due to
- mifepristone in the chromatogram obtained with solution (2) (1.0%).

Disregard all peaks with an area of less than the area of the peak due to 162 mifepristone in the chromatogram obtained with solution (3) (0.10 %). 163 **Assay.** Carry out the test as described under 1.14.1 Chromatography, High-164 performance liquid chromatography, using a stainless-steel column (4.6 mm x 25 165 cm) packed with particles of silica gel, the surface of which has been modified with 166 chemically-bonded octadecylsilyl groups (5 µm).² 167 Prepare a phosphate buffer pH 7.0 as described under "Related substances" 168 As the mobile phase, use a mixture of 50 volumes of the phosphate buffer pH 7.0 169 and 50 volumes of acetonitrile R. 170 Operate with a flow rate of 1.0 mL per minute. Maintain the column temperature 171 at 25 °C. Use an ultraviolet spectrophotometer set at a wavelength of 260 nm. 172 Prepare the following solutions, using as a diluent the mobile phase. 173 For solution (1), weigh and powder 20 tablets. Transfer a quantity of the powdered 174 tablets, nominally containing 200.0 mg of Mifepristone, into a 200 mL volumetric 175 flask. Add about 150 mL, sonicate for 5 minutes, and stir magnetically for an 176 additional 30 minutes. Cool to room temperature, dilute to volume, mix and filter. 177 Dilute 5.0 mL of the filtered solution to 100.0 mL with mobile phase. 178 For solution (2), transfer 50.0 mg of mifepristone RS into a 250 mL volumetric 179 flask, add 200 mL, sonicate for 5 minutes, cool to room temperature and dilute to 180 volume. Dilute 5.0 mL to 20.0 mL with mobile phase. 181 Inject 10 µL each of solutions (1) and (2) and record the chromatogram for 45 182 minutes. 183

² A Luna C18(2) column has been found suitable.

184	Measure the areas of the peaks corresponding to mifepristone obtained in the			
185	chromatograms of solutions (1) and (2) and calculate the percentage content of			
186	mifepristone (C ₂₉ H ₃₅ NO ₂) in the sample using the declared content of C ₂₉ H ₃₅ NO ₂ in			
187	mifepristone RS.			
188	Impurities			
189	The impurities limited by the requirements of this monograph include those listed in			
190	the monograph on Mifepristone.			
191				
192	Reference substances to be established.			
193	Mifepristone RS			
194	New International Chemical Reference Substance to be established.			
195	Mifepristone impurity B			
196	New International Chemical Reference Substance to be established.			
197				
198	***			